CONSENSUS

Development of UK recommendations on treatment for post-surgical erectile dysfunction

M. G. Kirby, I. D. White, J. Butcher, B. Challacombe, J. Coe, L. Grover, P. Hegarty, G. Jackson, A. Lowndes, H. Payne, J. Rees, V. Sangar, A. Thompson

SUMMARY

Aim: To develop a management strategy (rehabilitation programme) for postsurgical erectile dysfunction (ED) among men experiencing ED associated with treatment of prostate, bladder or rectal cancer that is suitable for use in a UK NHS healthcare context. Methods: PubMed literature searches of ED management together with a survey of 13 experts in the management of ED from across the UK were conducted. Results: Data from 37 articles and completed questionnaires were collated. The results discussed in this study demonstrate improved objective and subjective clinical outcomes for physical parameters, sexual satisfaction, and rates of both spontaneous erections and those associated with ED treatment strategies. Conclusion: Based on the literature and survey analysis, recommendations are proposed for the standardisation of management strategies employed for postsurgical ED.

Introduction

Prostate cancer is the most common male cancer, accounting for 24% of all new cancer diagnoses (1). Bladder cancer is the fourth most common cancer in male gender in the UK (1). Colorectal cancer is the third most common cancer in the UK (1), with about 50% of patients surviving for more than 5 years after treatment (2). Radical prostatectomy (RP) for prostate cancer, radical cystectomy (RC) plus urinary diversion for bladder cancer and surgery for colorectal cancer invariably lead to postsurgical erectile dysfunction (ED) (3–10).

In addition to a loss of erections, cavernous tissue damage following RP may result in significant reductions in penile length and circumference, and these changes have been shown to occur within the first few months of surgery (11–13). However, with the introduction of nerve-sparing (NS) surgery, erectile function (EF) can be preserved in a significant proportion of patients (14). Unfortunately, even with NS techniques, ED can still be a long-term and sometimes permanent complication for many patients.

What's known

Following surgery for prostate, bladder or rectal cancers, loss of erections and cavernous tissue damage may result in significant reductions in penile length and circumference, and these changes have been shown to occur within the first few months of surgery. However, with the introduction of nerve-sparing (NS) surgery, erectile function (EF) can be preserved in a significant proportion of patients. Unfortunately, even with NS techniques, ED can still be a long-term and sometimes permanent complication for many patients.

What's new

Currently, there are no UK-wide recommendations for postsurgical ED management strategies following treatment for prostate, bladder or rectal cancer. This study provides a brief overview of current strategies for postsurgical ED management and preservation of erectile function, based on a worldwide literature search. Literature review data are combined with recommendations from an expert panel – individuals who have used various strategies in their clinical practice – to propose evidence-based recommendations for standardised ED management that can be implemented effectively throughout the UK.

Disclosure

None of the authors has received any financial compensation for participating in the survey or writing this publication.
situation may lead to a loss of daily and nocturnal erections resulting in persistent failure of cavernous oxygenation and secondary erectile tissue damage associated with the production of pro-apoptotic factors (i.e. loss of smooth muscle) and pro-fibrotic factors (i.e. an increase in collagen) within the corpora cavernosa (14).

Most men or couples who seek ED treatment after surgery for colorectal, bladder or prostate cancer report difficulty in maintaining sexual activity and intimate relationships. Despite the presence of partners in nearly half of patient consultations, involvement of the partner has been shown to be minimal. Overall, discussions of wider psychosexual concerns are marginalised in medical consultations, and there are limited opportunities for couples to discuss the impact of RP on sexual functioning (20). Preoperative assessment of a couple’s readiness to engage in an ED rehabilitation programme is advisable (21). Patients want their partners to be included in the sexual rehabilitation process, but few institutions currently offer couple-based rehabilitation programmes (21). ED is an important cancer survivorship issue for men who have undergone RP and clinicians tend to underestimate patients’ distress and desire for early treatment (22).

Finally, assessing comorbidities that affect EF is also important, particularly in the presence of cardiovascular disease (CVD) risk factors. Studies have reported an association between sexual behaviour and comorbidities, such as CVD (23). Continued sexual function also has health benefits. For example, the Caerphilly Cohort Study demonstrated a 50% reduction in cardiac death with more than two orgasms per week (24). ED has an impact on partners and relationships. Sexual dissatisfaction was found to be a risk factor for myocardial infarction in a case-control study of women, with premature ejaculation or inability to get an erection in the male partner being the major underlying cause (25). ED is also independently associated with depressive symptoms in prostate cancer up to 4 years post diagnosis, indicating long-lasting psychological impact (26).

Management of postsurgical ED consists of preventing and/or treating ED after pelvic surgery by countering postsurgical pathophysiological changes during the period of neural recovery. Management of ED after surgery involves the use of any medication or device to maximise recovery of EF. Treating ED is important for endothelial and smooth muscle protection, neuromodulation and reduction in corporal fibrosis (27–31). Psychological and sexual counselling/psychosexual therapy have important roles in improving any biomedical rehabilitation and management programme for postoperative EF impairment (14). This is particularly so where the man/couple exhibit increased levels of distress or limited coping strategies.

The goal of EF management strategy is restoration of assisted and non-assisted EF and prevention of structural changes.

The current options for postsurgical ED management in the UK include:

- Oral medications [phosphodiesterase type 5 inhibitors (PDE5-Is: sildenafil, vardenafil or tadalafil)]
- Intracorporeal injections (ICI)
- Intraurethral suppository containing alprostadil that dilates the penile blood vessels
- Vacuum erection device (VED)
- Sexual counselling
- Pelvic floor exercises
- Combinations of the above
- Penile implant: malleable or inflatable as last resort.

**Rationale for recommendations development:**

The International Consensus of Sexual Medicine (ICSM) Committee recommends that clinicians instruct patients on the essential elements of the pathophysiology of postoperative ED (32). However, currently, there are no specific recommendations regarding the optimal rehabilitation regimen (32) or any standard guidelines for improving EF following surgery. Guidelines from the British Society of Sexual Medicine recommend PDE5-Is (e.g. sildenafil, tadalafil, vardenafil) for first-line treatment of men who have had a prostatectomy, but combination therapy is not discussed (33). With a growing number of sexually active patients undergoing RP or surgery for other pelvic cancers, and improvements in cancer survival rates, the restoration of sexual function has become increasingly important to men, couples and clinicians. On the basis of data presented here, it is reasonable to discuss the implementation of an ED rehabilitation programme (also called EF Restoration programme) for patients undergoing surgery. The ED rehabilitation programme should help preserve EF in men undergoing prostate, rectal or bladder cancer surgery. The goal of the programme is to provide men with improved and earlier return of natural or assisted erections following surgery.

**Methods**

**Literature analysis**

A review of published literature (papers published within the last 10 years) was carried out to determine current management options for postsurgical ED and establish the evidence grade for each option.
The studies identified and used in this literature analysis were graded using the Oxford Centre for Evidence-based Medicine – Levels of Evidence (34).

The literature search terms included various combinations of the following words: penile rehabilitation; erectile dysfunction/sexual function + cancer/prostate/rectal/bladder; sexual dysfunction + cancer/prostate/bladder/rectal; erectile dysfunction + prostatectomy; phosphodiesterase type 5 inhibitor + cancer; vacuum erection + cancer; alprostadil + cancer; intracorporeal injections + cancer; erectile dysfunction/sexual function + diet/exercise.

Reviews (except systematic reviews), commentaries and animal studies were excluded. Any studies that did not utilise surgical methods for the treatment of prostate/bladder or rectal cancer were excluded. All studies analysed used at least one intervention for postsurgical ED management/penile rehabilitation for ED.

Clinician’s survey
Recommendations from the group of authors were gained by conducting an email survey of current practice across England with 13 experts representing 10 organisations (listed at the end of this article). The survey investigated current practice in restoring or treating ED after surgery in prostate, bladder and rectal cancer patients, focusing on questions related to current clinical practice; scope of the problem in the UK and treatment approaches.

Results
PubMed search overview
The literature search identified 37 articles after applying the selection criteria. Both randomised and non-randomised studies were included (Table 1).

Studies and patient characteristics from the literature analysis
Of the 7725 patients included in the 37 selected studies (Table 1), 1937 were from the Cochrane review of conservative treatment and 5788 from other studies involving active treatment(s). All selected studies enrolled ≥ 15 patients. Most of the studies were non-randomised, uncontrolled studies. Postintervention follow up ranged from 12 weeks to ≥ 6 years (Table 1).

Presurgical assessment

Literature analysis
Partner involvement. There was a paucity of studies that included couple/partner assessment. An overview of these studies is summarised in Table 2.

The literature analysis demonstrated that patients who had partners with a negative sexual attitude lost sexual motivation up to 1 year after surgery (71). However, patients with cooperative partners maintained sexual motivation (71,72) and demonstrated improvements in measures of sexual function and quality of life (72). In addition, ED of the male partner was a significant risk factor for female sexual difficulty (73) and compliance with/dropout rates from rehabilitation protocols were related to partner preferences and preoperative female sexual function (69,73,74). Overall, there was a correlation between sexual dysfunction in female and male partners (75,76).

Clinician Survey findings. Table 3 outlines the baseline assessments of ED before surgery carried out by the clinicians surveyed:

The assessment usually involved:
• Discussion with patient.
• Biomedical components, including the disease, treatment, current medications, current medical history, previous medical and surgical history and medication history.
• Psychological factors (sexual self-esteem/confidence), relationship issues and any issues of a social context that impact on sexuality or that are affected by the sexual dysfunction, e.g. reduced penile size, loss of ejaculation.
• IIEF/SHIM/verbal – can patients have penetrative intercourse?

Most clinicians stated that partners were not always involved in assessment unless the patient consented to include them. However, patients were encouraged to take their partner to appointments in the ED clinic. ED assessment in clinical practice was generally driven by the urologist or surgeon and the multidisciplinary team.

Length of time from surgery to assessment and treatment
According to the literature analysis, the length of time from surgery to treatment varied from 1 week post surgery to ≥ 12 months. However, improved outcomes were observed with earlier treatment (within 1 month) of surgery or onset of ED especially with VED (43,44); PDE5-I (32,58); combination therapy (70).

In the survey analysis, four participants stated that early intervention was likely to lead to better results and improved return of EF and therefore would assess the patient at catheter removal or up to 10 days postoperatively. However, the interval from surgery to ED treatment varied in clinical practice and ED was assessed and managed up to 3 months after surgery in some cases. Re-assessment usually occurred at 8 weeks, 3 months and at 3 monthly
| Study | Level of evidence | No. of patients | Study design | Regimen | Start of treatment (after RP) | Duration/ follow up |
|-------|------------------|-----------------|--------------|---------|------------------------------|-------------------|
| **Conservative management** | | | | | | |
| Campbell et al. (Cochrane review) (35) | 1A | 1937 | Systematic review | Effects of conservative management for urinary incontinence after prostatectomy (sexual rehabilitation was included but not main focus) | Varied | Varied |
| **Intracorporeal injections** | | | | | | |
| Montorsi et al. (36) | 1B | 30 | RCT | ICI three times per week for 12 weeks vs. no treatment | 1 month post surgery | 6 months |
| Mulhall et al. (37) | 3B | 132 (58 active treatment vs. 74 in no treatment group) | Non-randomised study | Trimix/Bimix three times per week vs. no treatment or as needed (nonresponders switched to sildenafil) | 4 months post surgery | 18 months |
| You et al. (38) | 4 | 87 | Uncontrolled cohort study | 2.5 μg intracavernous alprostadil injection | 1 month | 12 months |
| **Intraurethral** | | | | | | |
| PGE-1/Alprostadil | | | | | | |
| Costabile et al. (39) | 2B | 384 | Controlled clinical trial | Intraurethral PGE-1 initially then active drug vs. placebo | ≤ 3 months after surgery | 3 months (follow up) |
| Gontero et al. (40) | 4 | 76 | Randomised study | 20 mg prostaglandin E1 injection vs. MUSE (125 or 250 μg three times per week) vs. on-demand treatment | 1–12 months | 12 months |
| Raina et al. (41) | 4 | 91 | Case comparison study | Transurethral alprostadil (PGE1) (MUSE) four times per month | 3 weeks | 6 months |
| Raina et al. (42) | 4 | 54 | Case series (single cohort) | | | |
| **Vacuum erection device** | | | | | | |
| Köhler et al. (43) | 1B | 28 | RCT | Daily VED (10 min), early vs. delayed after RP | 1 month after RP vs. 6 months after RP | 6 months |
| Raina et al. (44) | 1B | 109 | RCT | VED twice a week vs. no treatment | 1 month | 9 months |
| **Phosphodiesterase type 5 inhibitor (PDE5i)** | | | | | | |
| Aydogdu et al. (45) | 1B | 65 | RCT | Tadalafil vs. No treatment | 1 week | 6–12 months |
| Bannowsky (46) | 1B | 43 | RCT | Nightly sildenafil 25 mg/day vs. control (no sildenafil) | After catheter removal (7–14 days) | 12 months |
| Brock et al. (47) | 1B | 440 | RCT | Vardenafil, 10 and 20 mg vs. placebo | 6 months–5 years post surgery | 3 months |
| McCullough (48) | 1B | 139 | RCT | Intraurethral alprostadil or oral sildenafil citrate (50–100 mg) | Within 1 month | 9 months |
| Montorsi (49) | 1B | 628 | RCT | Placebo, nightly vardenafil, or on demand vardenafil | | |
| Montorsi et al. (50) | 1B | 303 | RCT | Tadalafil 20 mg, on demand vs. placebo | 12–48 months | 3 months |
| Mosbah et al. (51) | 1B | 18 | RCT | Sildenafil twice per week to be shifted to ICI of PGE1 in not responders | 2 and 6 months post surgery | 6 months |
| Nehra et al. (52) | 1B | 440 | RCT | Placebo, 10 mg vardenafil or 20 mg vardenafil | 4 weeks | 3 months |
| Pace et al. (53) | 1B | 40 | RCT | Flexible-dose sildenafil vs. no treatment | 14 days | 6 months |
| Padma-Nathan et al. (54) | 1B | 76 | RCT | Sildenafil, 50 or 100 mg, daily and nightly | 4 weeks | 9 months |

© 2013 The Authors International Journal of Clinical Practice Published by John Wiley & Sons Ltd
Int J Clin Pract, May 2014, 68, 5, 590–608
Table 1 Continued

| Study                           | Level of evidence | No. of patients | Study design          | Regimen                                                                 | Start of treatment (after RP) | Duration/ follow up |
|---------------------------------|-------------------|-----------------|------------------------|-------------------------------------------------------------------------|-------------------------------|---------------------|
| Rectal cancer: Lindsey (55)     | 1B                | 32              | RCT                    | Sildenafil vs. placebo                                                  | 5.6 years                     | 1 month             |
| Briganti et al. (56)            | 2B                | 435             | Single cohort          | Test the effects of:                                                   | Varied                        | 36 months           |
| Müller (57)                     | 2C                | 92              | Retrospective database analysis | Sildenafil or ICI therapy                                                  | Within 12 months              | 18 months           |
| Schwartz et al. (58)            | 3B                | 40              | Case control study     | 50 mg sildenafil and 100 mg sildenafil every other night                  | At catheter removal           | 6 months            |
| Briganti et al. (59)            | 4                 | 435             | Single cohort          | PDE5-I treatment schedule (daily and on-demand)                        | Varied                        | 36 months (treatment) |
| Mulhall (60)                    | 4                 | 48              | Single cohort          | Sildenafil, and if unsuccessful, then ICI                               | < 6 months (early) vs. ≥ 6 months after RP (delayed) | 24 months           |
| Zippe et al. (61)               | 4                 | 49              | Survey                 | Sildenafil -- varied                                                   | Immediately; 6 and ≥ 12 months | 12 months           |
| NS radical cystectomy: El-Bahnasawy et al. (62) | 4 | 100 | Open-label, study | 50 and 100 mg sildenafil                                               | N/A                           | N/A                 |
| Rectal cancer: Nishizawa (10)   | 4                 | 207             | Single cohort uncontrolled study | On demand treatment with sildenafil                                      | 3 months                     | 12 months           |

**Combination therapy**

| Study                           | Level of evidence | No. of patients | Study design          | Regimen                                                                 | Start of treatment (after RP) | Duration/ follow up |
|---------------------------------|-------------------|-----------------|------------------------|-------------------------------------------------------------------------|-------------------------------|---------------------|
| Titta et al. (63)               | 1B                | 57              | RCT                    | Sexual counselling + PGE1-ICI therapy vs. only ICI                      | ~1 month                      | 18 months           |
| Mydlo et al. (64)               | 2B                | 34              | Retrospective study    | Sildenafil or vardenafil. After a max of eight doses treated with ICI therapy using 15 or 20 mg alprostadil + oral therapy | Varied                        | 7 months            |
| Yassin et al. (65)              | 3B                | 69              | Controlled study, non-randomised | Sildenafil, 25 mg three times per week or tadalaflit, 5 mg, twice weekly + VED twice daily | 11 days                      | 3 months            |
| Basal et al. (66)               | 4                 | 203             | Retrospective case series | Review of patients on penile rehab                                      | Varied                        | 15–72 months        |
| Kimura et al. (67)              | 4                 | 676             | Case series            | PDE5I + VED – review of factors affecting rehab                         | N/A                           | N/A                 |
| Lee et al. (68)                 | 4                 | 77              | Case series            | Sildenafil citrate or tadalaflit three times per week                   | Varied                        | 8 months            |
| Moskovic et al. (69)            | 4                 | 29              | Case series            | Sildenafil 25 mg nightly + 250 µg alprostadil suppository three times per week. At 1 month, additional daily use of VED (10 min/day) + 100 µg of sildenafil on demand prior to sexual attempt | Prior to surgery and 3 days after RP | 6 months            |
| Nandipati et al. (70)           | 4                 | 22              | Uncontrolled study     | Sildenafil 50 mg/day at discharge + PGE1-4 µg or low-dose Trimix (20 U) two to three times per week | At hospital discharge          | 12 months           |

RP, radical prostatectomy; RCT, randomised controlled trial; VED, vacuum erection device; ICI, intracorporeal injection.
intervals thereafter, usually coinciding with the men’s cancer treatment review schedule.

Very few participants assessed ED presurgery, although most recognised the need to do so. All participants assessed patients for comorbidities and concurrent drug therapy, which may affect ED and response to ED management. Testosterone levels were not routinely checked in clinical practice unless there was a clear indication to do this.

Current available management strategies for postsurgical ED
Current management strategies for ED are summarised in Table 4.

### Table 2 Studies that assessed partners pre- and post pelvic surgery

| Study                  | Investigations                                                                 | No. of patients |
|------------------------|-------------------------------------------------------------------------------|-----------------|
| Claes et al. (72)      | Erection Hardness Score (EHS)                                                 | 447             |
|                        | International Index of Erectile Function (IIEF)                               |                 |
|                        | Self-esteem And Relationship (SEAR) questionnaire                           |                 |
|                        | Sexual Life Quality Questionnaire (mSLQ-QOL)                                 |                 |
| Davison (21)           | IIEF                                                                          | 143             |
|                        | Miller Social Intimacy Scale (MSIS)                                          |                 |
| El-Meliegy et al. (77) | Partner Relationship Questionnaire                                           | 493             |
| Jiann et al. (73)      | Female Sexual Function Index (FSFI)                                          | 2159            |
| Moskovic et al. (69)   | Compliance with intracorporeal injections                                    | 29              |
|                        | Sexual Health Inventory for Men (SHIM)                                        |                 |
|                        | Female partners completed the Female Sexual Function Index (FSFI)            |                 |
| Neece et al. (76)      | Survey                                                                        | 320             |
| Polito et al. (78)     | IIEF                                                                          | 430             |
| Rubio-Aurioles et al. (71) | Partner Relationship Questionnaire                                         | 511             |
| Sato et al. (79)       | Patients’ sexual function, sexual bother and expectations for postoperative sexual life | 162             |
| Schover et al. (74)    | Sexual Self-Schema Scale-Male Version                                       | 2636            |
|                        | IIEF                                                                          |                 |
|                        | Urinary and bowel symptom scales from the Los Angeles Prostate Cancer Index  |                 |
|                        | Short-Form Health Survey                                                     |                 |
| Shindel et al. (75)    | IIEF                                                                          | 1134            |
|                        | FSFI                                                                          |                 |

### Table 3 Survey findings of baseline assessments of EF before surgery

| Assessment                                      | No. of responders |
|------------------------------------------------|-------------------|
| IIEF/SHIM                                       | 6                 |
| Verbal sexual history take only                 | 5                 |
| Surgical nurse assessment                      | 1                 |
| (depends on nurse availability)                 |                   |
| Partner consultation                            | 1                 |

EF, erectile function; IIEF/SHIM, International Index of Erectile Function/Sexual Health Inventory for Men.

### Treatment regimens for nerve-sparing vs. non-nerve-sparing surgery
Clinicin survey findings of strategies employed in clinical practice for managing ED associated with NS and non-NS surgery are summarised in Table 5.

### Treatment algorithm
A typical treatment algorithm employed in clinical practice and provided by most of the survey participants for NS prostatectomy and for non-NS surgery is shown in Figure 1A, B, respectively. The algorithms shown are mainly based on locally agreed practice.

### Advantages and disadvantages for each postsurgical ED management strategy
The advantages and disadvantages for each postsurgical ED management strategy are summarised in Table 6.

### Duration of treatment
In the literature analysis, the duration of treatment lasted from 6 months to ≥ 6 years.
According to the survey findings, the duration of any treatment can range from 3 months until the patient no longer needs the treatment. The duration of time for any treatment may depend on various factors including patient acceptance, need for treatment, side effects or simply access to and cost of the treatment.

There is no clear evidence of the optimal length of treatment with daily dosing in the literature and in clinical practice; this varies from patient to patient. Hence, the decision to stop treatment must be individualised and strict or arbitrary time limits are inappropriate.

**Discussion**

The literature search identified 37 articles after applying the selection criteria. Both randomised and non-randomised studies were used. However, it must be noted that most studies identified were non-randomised or controlled studies.

---

**Table 4** Current management strategies for postsurgical ED from literature analysis

| Strategy                   | No. of publications | Total no. of patients | Results                                                                 | Adverse events                                      |
|----------------------------|---------------------|-----------------------|-------------------------------------------------------------------------|-----------------------------------------------------|
| Conservative management    | 1                   | 1937                  | No significant benefit from pelvic floor exercises for ED (35)          | N/A                                                 |
| Psycosocial counselling     | 1                   | 57                    | Significant improvements in IIEF scores when combined with ICI injections (63) | Prolonged erection/penile nodule (n = 3) (36,63) |
| Intracorporeal injections   | 5                   | 382                   | Significant self-reported recovery of spontaneous erection sufficient for satisfactory sexual intercourse (36,37,40) | Painful erections (n = 10) – pain decreased over time in one study (38,63) |
| Intraurethral PGE-1/Alprostadil | 3   | 529                   | Achieved erections sufficient for intercourse (39,41,42) | Urethral pain/burning (39,41,42)                  |
| Vacuum erection device      | 2                   | 137                   | Significant improvements in IIEF scores, especially with early use (43,44) | Difficulties in using the device (80)          |
| Phosphodiesterase type 5 inhibitor (PDE5-I) | 18       | 4977                  | Preserved penile length (45) Significant improvements in IIEF with on demand and daily therapy (47-50,52-57,62) | Headache, flushing and rhinitis with PDE5-Is (47,50,52) |
|                             |                     |                       | No difference in terms of EF recovery was found between patients receiving on-demand vs. daily PDE5-I (56) | Dyspepsia and myalgia with tadalafil (50)          |
|                             |                     |                       | Higher efficacy with daily therapy vs. on-demand PDE5-I in patients with intermediate risk of ED (56) |                                                     |
|                             |                     |                       | Treatment schedule correlates with ED risk (higher risk patients benefit from daily therapy) (56) |                                                     |
|                             |                     |                       | Erections sufficient for successful penetration (50–52,62) |                                                     |
|                             |                     |                       | Recovery of unassisted erections (51,53,54,57) |                                                     |
|                             |                     |                       | Significant differences between early vs. delayed therapy (58,60) |                                                     |
|                             |                     |                       | Responsiveness to PDE5-I may persist for 8 h post dose in men with mild-to-moderate ED (48) |                                                     |
| Combination therapy         |                     |                       | Return of spontaneous erections (69) Significant improvements in SHIM scores (64,70) |                                                     |
|                             |                     |                       | Early therapy associated with improved outcomes (70) |                                                     |
|                             |                     |                       | Early combination therapy with PDE5-I allowed lower dose of intracavernous injections (70) |                                                     |
|                             |                     |                       | Erections sufficient for intercourse (65) |                                                     |

ED, erectile dysfunction; ICI, Intracorporeal injection; IIEF, International Index of Erectile Function; EHS, Erection Hardness Score; PDE5-I, phosphodiesterase type 5 inhibitor; SHIM, Sexual Health Inventory for Men.
Goals of postsurgical ED management/
restoring EF
All the participants of the clinician survey agreed that the goals for postsurgical ED management should be:
• Restoration of normal, assisted or non-assisted EF
• Achievement of an erection that is satisfactory for
the patient for masturbation or penetrative sexual purposes
• Achievement of patient-agreed sexual recovery goals
  ▪ Establish the patient’s expectations/recovery goals
  ▪ Establish the couple’s expectations/recovery goals
  ▪ Be realistic when managing patient/couples’ expectations
• Improvement of specific ED-related quality of life issues, e.g. stress/depression
• Provision of ongoing support for the man/couple relating to the sexual consequences of their cancer treatment
• Maintenance of blood flow to the penis and maximisation of the potential for cavernosal nerve repair to enable natural penetrative EF, prevent penile shortening, endothelial damage and promote re-oxygenation of tissue.

Predictive factors
The recovery of EF is a multifactorial process that depends on many variables (81,82). These include:

Table 5
Survey analysis of treatment strategies for nerve-sparing vs. non-nerve-sparing surgery

| Nerve-sparing | Non-nerve-sparing surgery |
|---------------|----------------------------|
| First-line strategy used | First-line |
| PDE5-I once daily/on demand +/- VED | Sexual and relationship therapy or VED |
| Second-line strategy used | VED + ICI/Intraurethral alprostadil |
| (probably second line and ICI third line) | Exclude PDE5-I, all other treatments may work |
| Third-line strategy used | Second-line |
| Penile prosthesis | Penile prosthesis |

VED, vacuum erection device; ICI, intracorporeal injection; PDE5-I, phosphodiesterase type 5 inhibitor.

Figure 1
Erection Restoration Algorithm. *Algorithm is a collation of survey responses based on individual clinical practice of authors. **Psychosexual therapy and counselling provided as an adjunct to ED treatment. †Pelvic floor exercise advice also provided by physicians.
- Patient and partner age – older age is associated with ED
- Preoperative EF (including preoperative use of PDE5-I – better preoperative function is associated with better outcomes
- Comorbidity status at the time of surgery (fewer comorbidities are associated with lower risk of ED)
- Surgical technique (plan for NS surgical technique: unilateral/bilateral or not)

- Prostate-specific antigen level (lower levels associated with better outcomes)
- Lower cancer grade/risk category associated with better outcomes
- African American race/ethnicity and lower body mass index are associated with better EF
- Testosterone levels – normal levels are important for recovery of EF

---

Table 6 Advantages and disadvantages for each postsurgical ED management strategy

| Post-surgical ED management strategy | Advantage | Disadvantage |
|-------------------------------------|-----------|--------------|
| Oral medications (PDE5-I)           | Easy to take Acceptable to most patients and partners Generally good response Safe – Good tolerance generally Does not interfere with foreplay | Side effects, e.g. muscle aches, headaches Some patients will need to take the drug on at least 8–12 occasions to achieve a reliable response Compliance Treatment failure Cost Un-licensed indication for daily dosing in ED rehabilitation programme |
| Vacuum erection device              | Avoids medication – may be more acceptable to some men Non-invasive Safe – no systemic effects or medical toxicity Cost-effective Simple to use Can be effective but depends on patient acceptability | Uncomfortable, clumsy, mechanical Erection not natural looking Commitment to learn Skilled instructor needed Slow response Partner acceptance If used for penetration: altered penile sensations Can be painful |
| Intraurethral suppository            | Relatively easy to use and learn Rapid onset May not be effective for all patients No needles Painless to insert Well-tolerated Local treatment | Not helpful for most men Can be difficult to insert Urethral burning |
| Intracorporal injections             | More natural looking erection Quick administration and result Usually effective – direct drug delivery | Compliance Psychological – not acceptable to all men or their partners Requires motivated patient Good manual dexterity needed Skilled instructor needed Patient fear of priapism Pain and bruising, recommended precautions |
| Combination strategy                | May be helpful for those with incomplete erections with PDE5-I alone Easy to use Problems as above with the differing combinations therefore additive Seems to be the most effective, allows early resumption Works on all aspects of postoperative ED | Need for two separate interventions Patient commitment Expensive and time consuming Not always available on the NHS |

ED, erectile dysfunction; PDE5-I, phosphodiesterase type 5 inhibitor.
Assessment of EF
The results from the literature analysis and the survey support the finding that the partner’s sexual function should also be assessed as part of any ED management programme because partners may require intervention if they are to support rehabilitation efforts for their spouses (21).

The ICSM 2001 recommends that clinicians discuss ED prevalence rates, the pathophysiology of ED after RP and the predictors of EF recovery. They also propose that validated instruments and published cut-offs for normal function should be used for baseline and subsequent assessment, and that sexual rehabilitation and its potential benefits should be discussed with patients (60).

A list of some of the tools available for clinicians to assess baseline sexual function and track the progress of patients (and partners) over therapy is shown in Table 7. However, a detailed assessment is not necessarily carried out in each case. In the clinician survey, most participants confirmed that they evaluate patients presurgery via verbal assessment or through IIEF/SHIM questionnaires.

According to the clinician survey findings, most participants would evaluate patients presurgery via verbal assessment or through IIEF/SHIM questionnaires [although many did not carry out ED assessment presurgery (n = 6)]. The survey showed that assessment can begin before surgery or at catheter removal (up to 3 months after surgery).

Inclusion of other assessments, e.g. biomedical tests, depended on the clinician’s speciality. Involvement of partners at assessment, although recommended in the literature, depended on patient agreement in clinical practice.

Assessing the partners’ sexual function is important in managing ED. Satisfactory preoperative female partner sexual function has been shown to correlate with greater patient compliance with the localised component of the EF rehabilitation programme (69). There is a paucity of data from research in same sex partnerships. However, sexual health assessment for partners should also be performed to ensure that the proposed couple recovery programme is appropriate.

There is a significant correlation between postoperative sexual life of patients and their partners. Partners’ cooperative attitude might contribute to maintaining patients’ sexual desire and motivation. Survey data show that patients wish their partners to be included in the sexual rehabilitation process, but few institutions currently offer couple-based rehabilitation programmes (21). Although intimacy levels of couples are high preoperatively, there is a need to prospectively determine how these levels are impacted by changes in sexual function postoperatively. Baseline assessment of a couple’s sexual function and willingness to participate in an EF management programme should ideally be performed preoperatively (21).

Once ED management is initiated, the clinicians surveyed recommend that re-assessment should occur regularly (at least every 3 months).

Management of ED post surgery
The restoration of EF usually involves proactive and early management strategies to:

- Minimise severity/duration of ED
- Improve cavernosal oxygenation
- Promote endothelial protection
- Prevent/minimise cavernosal structure changes

The ICSM Committee has listed five different types of rehabilitative approaches: (i) phosphodiesterase type 5 inhibitors (PDE5-Is), (ii) ICIs, (iii) intrarethral alprostadil, (iv) VED, and (v) neuromodulatory agents, although no specific recommendation was given regarding the optimal rehabilitation regimen (60).

| Table 7 Overview of some commonly used sexual function assessment tools |
| --- |
| Survey name                          | Abbreviation | Number of items | Domains                                      | Estimated time to complete (min) |
| International index of erectile function (83) | IIEF        | 15              | Erectile function, Orgasmic function, Sexual desire, Intercourse satisfaction | 3                             |
| Sexual health inventory in men (84) | SHIM (IIEF-5) | 5               | Erectile function, Intercourse satisfaction | 1                             |
| Erection hardness scale (85,86)      | EHS         | 1               | Assessment of erection hardness              | 1                             |

© 2013 The Authors International Journal of Clinical Practice Published by John Wiley & Sons Ltd
Int J Clin Pract, May 2014, 68, 5, 590–608
Current strategies
Current strategies for managing ED in the UK include:

- PDE5 inhibitors
- ICI
- Intraurethral alprostadil
- VED
- Psychosexual therapy
- Physiotherapy (pelvic floor exercises)
- Penile implants/prosthesis
- Combinations of the above

Oral therapy – PDE5-Is
PDE5-Is commonly used for treating ED post surgery include sildenafil, tadalafil and vardenafil. In men with ED, postbilateral NS RP, sildenafil, vardenafil and tadalafil are all equally effective treatments, although most of the trials conducted to date have been performed with sildenafil (49,50,87). Furthermore, PDE5-Is are not currently licensed for use in men for ED rehabilitation programmes.

A multicentre, placebo-controlled, 12-week, parallel arm randomised trial of 440 men compared placebo with vardenafil, 10 and 20 mg. At 12 weeks, improved erections (based on GAQ) were reported by 65.2% and 59.4% of patients on 20 and 10 mg vardenafil, respectively, and by only 12.5% of patients on placebo (p < 0.0001) (47). Tadalafil 20 mg administered as needed for 12 weeks was well tolerated and was effective in the treatment of ED when initiated 12–48 months following prostatectomy (50). The duration of action following 100 mg sildenafil may persist for 8 h post dose in men with mild-to-moderate ED (48).

McCullough et al. have reported the results of a prospective, randomised, open-label, multicentre study comparing nightly intraurethral alprostadil and oral sildenafil in men with preoperative fully normal EF who underwent NS RP (48). Both nightly treatments were started ≥1 month after surgery, at the catheter removal visit, and continued for nine consecutive months. At months 3 and 6, there was a 7–14% difference in IIEF scores in favour of IUA, but the differences were not significant. Mean IIEF scores were not significantly different in the two groups at the end of the study (IUA 15.28 vs. sildenafil 17.65). Overall, there were no statistically significant differences between the two groups in terms of IIEF-EF domain scores and intercourse success rates (48).

Pace et al. investigated EF recovery of patients treated by early penile rehabilitation therapy (14 days post surgery) with sildenafil vs. a no treatment control group (53). The treatment was initiated 14 days after surgery. Significant differences in IIEF mean scores improvements were observed with sildenafil vs. control group at 24 weeks. The authors concluded that PDE5-Is should be offered early after RP to support recovery of EF. A study by Mulhall et al. also suggested a benefit from early pharmacological rehabilitation with sildenafil after RP (60). Early institution of tadalafil therapy after RP also appeared to preserve EF and speed the return to sexual intercourse (88).

Current data show that sildenafil (89,90), tadalafil (50,89) and vardenafil (47,52,89) taken when needed may improve ED post RP. On-demand treatment with vardenafil during a 3-month period significantly improved intercourse satisfaction, orgasmic function and overall satisfaction with sexual experience (52).

Daily therapy has shown similar benefits (91). Bedtime sildenafil (50–100 mg daily) administration for nine consecutive months, beginning 1 month postoperatively, results in a greater return to baseline EF and improvements in spontaneous erections (54). Bannowsky et al. further demonstrated that sildenafil was effective in cases of early postoperative nocturnal erections (46). Montorsi et al. showed that sildenafil taken nightly enhances nocturnal penile tumescence after RP (92).

Briganti et al. (59), in a large contemporary series of patients treated by high-volume surgeons, showed that the 3-year EF recovery rates were significantly higher in patients who used postoperative PDE5-Is compared with patients who did not use any postoperative PDE5-Is (73% and 37%; p < 0.001), regardless of the class of risk to which patients belonged according to their own preoperative characteristics. However, EF recovery rates were not significantly different according to the PDE5-I treatment schedule (daily compared with on-demand) after NSRP. In addition, a randomised, double-blind, double-dummy, multicenter, parallel group study compared 9-month 10-mg nightly dosing of vardenafil and flexible-dose on-demand vardenafil (starting at 10 mg, with the option to titrate to 5 or 20 mg) in patients who had a NSRP (49), showed that nightly dosing with vardenafil did not have any effect beyond that of on-demand use.

Another study that tested the effect of penile rehabilitation according to preoperative patient characteristics in 435 patients demonstrated that although there was no difference in terms of EF recovery between patients receiving on-demand vs. daily PDE5-I; in patients with low or high risk of ED risk of ED, daily therapy showed significantly higher efficacy for the EF recovery rate compared with the on-demand PDE5-I administration schedule in patients with intermediate risk of ED (56).

Early high-dose therapy with sildenafil may preserve the smooth muscle content within the corpora cavernosa.
osa in humans (58). In addition, tadalafil rehabilitation is effective in preserving penile size especially in the early postoperative period after surgery (45).

In a study designed to assess the efficacy and safety of sildenafil for managing ED following RC, sildenafil therapy significantly improved the ability to achieve and maintain an erection, with a dose-dependent response (62).

A study, carried out to determine the extent of male sexual dysfunction after surgical treatment of rectal cancer and to examine the outcome of postoperative treatment with sildenafil in 207 patients, demonstrated that on-demand sildenafil was effective in improving ED (10). A double-blind placebo-controlled study aimed to determine the efficacy of sildenafil after rectal excision for cancer or inflammatory bowel disease in 32 patients. In this study, sildenafil completely reversed or satisfactorily improved postproctectomy ED in 79% of patients (55).

In summary, the likelihood of response to PDE5-Is increases with time, and has been shown to be ineffective in the first 6–9 months post RP in some studies (93). The response rates to sildenafil after RP depend on age, dosage, interval to start of therapy and degree of cavernous nerve damage (93). Although younger patients with good preoperative EF may experience good EF recovery rates even without any treatment, using PDE5-Is after surgery further improves their functional outcomes (14,94). Treating patients immediately postoperatively is important and may lead to better long-term results in terms of either EF recovery or ED treatment (14). Furthermore, early use of sildenafil after RP may preserve intracorporeal smooth muscle content (53,58,60). The literature analysis and survey results suggest that PDE5-Is should be offered early after RP to allow the recovery of EF (58). PDE5-Is could be initiated as early as the removal of the catheter or during the very first month after surgery (14).

Although daily use of PDE5-Is has shown better efficacy data vs. on-demand use in patients with intermediate risk of ED (56), high-quality RCTs are lacking, which compare on-demand vs. daily use of PDE5-Is. Studies emphasise that early management of ED prior to penile fibrosis development is important (14). There is evidence for a protective role with prolonged dosage of a PDE5-I for preventing cavernosal damage in animal models (27,29,30,95,96). For example, both sildenafil and tadalafil decrease numbers of apoptotic cavernous smooth muscle and endothelial cells and increase numbers of kinases associated with cellular survival in animal models (28,96). Early high-dose use of PDE5-Is has shown to preserve smooth muscle content within the corpora cavernosa in humans and they may also help preserve penile size (45,58,97). Long-term use of PDE5-Is post cavernosal nerve resection has been shown to prevent the alterations in corporal histology induced by cavernosal nerve damage (20,96).

Specific counselling on ED treatment modalities and re-education of patients could promote higher initial acceptance rate and a reduction in the postoperative discontinuation rate for PDE5-Is (98).

**Intracorporeal injection**

Montorsi et al. compared regular administration of alprostadil ICIs vs. no injection therapy postoperatively in a total of 30 patients. The patients were randomized to alprostadil injections three times per week for 12 weeks (15 patients) or observation without any erectogenic treatment (15 patients). Six months post RP, spontaneous sexual erections were reported in significantly more men who had undergone routine ICI compared with those who did not (36). In the alprostadil group, eight patients (67%) reported the recovery of spontaneous erection sufficient for satisfactory sexual intercourse, compared with three patients (20%) in the control group (p < 0.01) (36). In a prospective non-randomised study, Mulhall et al. evaluated the postoperative outcome of men with functional preoperative erections who underwent either NS or non-NS RP and were provided with early postoperative oral sildenafil (within 6 months after RP) (37). Non-responders were switched to ICI (TriMix) three times a week or on-demand use 4 months after surgery. At 18 months after RP, all patients who had used TriMix did not report either pain or prolonged erections (priapism) (37). Furthermore, the injections significantly improved the proportion of patients responding to sildenafil (patients who followed the protocol = 64% vs. patients who did not follow the protocol = 24%, p < 0.001). These data indicate that a pharmacological penile rehabilitation protocol results in higher rates of spontaneous functional erections and erectogenic drug response after RP (37).

In a prospective study, Yiou et al. assessed the safety and efficacy of intracavernosal alprostadil (2.5 mg of alprostadil twice a week) in a cohort of 87 men who underwent laparoscopic NS RP and started self-injection treatment 1 month after surgery (38). The alprostadil dose was titrated up until the patients were able to achieve an erection hard enough to allow vaginal penetration; it was also suggested that patients attempt intercourse as often as possible. 11% of patients discontinued because of painful erections. Among those who continued the treatment, pain intensity during erection and pain scores significantly decreased over time (i.e. between 6 and 12 months after RP). In contrast, pain scales did not correlate signifi-
cantly with any of the sexual scores at 12 months, suggesting that the adverse impact of pain diminished over time (38).

Montorsi et al. published a study supporting use of ICIs of alprostadil three times weekly for 12 weeks after RP with those using no treatment. The study showed that early postoperative administration of alprostadil injections significantly increased the recovery rate of spontaneous erections after NS radical retropubic prostatectomy (36).

In men who received a non-nerve-sparing RP (NNSRP), Gontero et al. showed a trend towards a progressively decreasing erectile response with time from the operation (40). A total of 73 patients received prostaglandin E1 injections at 1, 2–3, 4–6 and 7–12 months postoperatively. A significantly higher proportion of patients who received the injections in the first 3 months after surgery had erections hard enough for penetration compared with patients who received the injections at 4–12 months after surgery. However, injection given in postoperative month 1 provided the best response rate but with significant complications and poor patient compliance. Gontero et al. concluded that patients who received ICI ≤ 3 months after RP achieved an erection sufficient for sexual intercourse; after that period of time, the chances of an acceptable response to alprostadil decreased (40). The authors further suggested that 3 months post surgery is a reasonable compromise to start treatment in terms of effectiveness and patient compliance (40).

Intracorporeal injection is usually the treatment of choice for patients in whom PDE5-Is are relatively ineffective (14). The timing for starting ICI, like any other ED intervention, should be accurately defined (14). ICI can often cause penile discomfort, which affects patient compliance (14).

Intraurethral alprostadil
Costabile et al. evaluated erectile response rates to intraurethral PGE-1 beginning at least 3 months after RP (39). Approximately 70% of treated men developed erections sufficient for intercourse. The responders were then randomised into a 3-month home trial with either PGE-1 or placebo. Approximately 57% of the patients in the PGE-1 group had erections sufficient for intercourse vs. 6.6% in the placebo group (39).

Zippe et al. conducted a prospective non-randomised study on the early use of intraurethral alprostadil after RP in 91 patients who received intraurethral alprostadil three times/week for the first 6 weeks after RP vs. control group (no intraurethral alprostadil). At 6 months, 74% of the patients resumed sexual activity, 53% had natural erections sufficient for vaginal penetration without intraurethral alprostadil and 47% continued to use intraurethral alprostadil as an adjuvant treatment for successful intercourse. In the control group, only 11% of patients at 6 months achieved natural erections sufficient for satisfactory sexual intercourse (61). The intraurethral alprostadil discontinuation rate was 32% (61). Raina et al. evaluated 54 patients from a single surgical series who used intraurethral alprostadil 6 months after RP (42). Overall, 55% of patients achieved and maintained erections sufficient for intercourse, 48% continued long-term therapy with a mean use of 2.3 years (average usage of four times per month) and there was a 61% spousal satisfaction rate (42). The intraurethral alprostadil discontinuation rate was 52% (42).

The most common reasons for discontinuation of intraurethral alprostadil were insufficient erections, switch to other ED therapies, natural return of erections, and urethral pain and burning (42,61).

Intraurethral PGE-1/alprostadil has been shown to be an effective therapy for post-RP ED, especially when treatment is initiated early (39). Early intraurethral alprostadil therapy following RP is associated with increased frequency of sexual activity, and increased incidence of natural erections sufficient for intercourse (39,61).

Vacuum erection device
Raina et al., in a non-randomised study of 109 patients at the Cleveland Clinic, evaluated the use of early VED after prostatectomy (1 month after surgery). They demonstrated that 23% of patients compliant with VED treatment complained of decreased penile length and girth as compared with 85% who were non-compliant (44). This was consistent with a previous study, which assessed the efficacy of VED, daily for 9 months, following RP (44). The study had demonstrated that early use of VED following RP facilitates early sexual intercourse, early patient/spouse sexual satisfaction and potentially an earlier return of natural erections sufficient for vaginal penetration (44). Köhler et al. looked at early (starting 1 month after prostatectomy) vs. late (starting 6 months after prostatectomy) usage of the VED. The VED was used for a total of 5 months after RP, and showed an improvement in IIEF scores and stretched penile length in the early usage group (43).

In summary, the literature analysis has shown that initiating the use of a VED protocol at 1 month after RP can improve early sexual function and help preserve penile length (43). The literature analysis shows that early use of VED (within 1 month of surgery) can lead to significant improvements in IIEF and sexual function (43,44). In these studies, the VED was effective at restoring erections and maintaining...
penile size when therapy was initiated at 1 month or between 2 and 8 weeks (mean 3.9 weeks) after surgery (43,44). Therefore, 4–8 weeks may be considered an appropriate postoperative recovery period, and VED can possibly be initiated after this time. VEDs are often effective, low-cost treatment options for ED. They are cost-effective compared with PDE5-Is (99). However, there are no head-to-head trials examining VED vs. oral therapy.

**Psychosexual therapy and counselling**

In a prospective study, a cohort of 57 patients who completed the IIEF 1 month after RP were randomised to either treatment with ICI only or ICI-focused sexual counselling for 18 months (63). At the end of the study protocol, the analyses showed that men who received sexual counselling coupled with ICI therapy reported the best quality in all IIEF domain, the lowest discontinuation rate and the highest degree of couple’s satisfaction compared with men who did not receive any formal counselling (63). Sexual counselling reduced patients’ feeling of lack of sexual spontaneity, dissatisfaction and fear of needles (63).

Psychological and sexual counselling may also play an important role in improving any rehabilitation and management programme of postoperative EF impairment (14). Many studies have shown that sexual counselling contributes to better biomedical treatment efficacy, patient acceptance and compliance (14,40,63,99–101).

**Pelvic floor exercise**

A Cochrane review, which assessed the effects of ‘conservative’ management for urinary incontinence after prostatectomy, concluded that there was no evidence of benefit for ED with pelvic floor muscle training (35).

**Combination therapy**

Mydlo et al. retrospectively reviewed 34 men after RP with subsequent ED (64). Patients were titrated on sildenafil or vardenafil to maximum doses. All had a suboptimal response and were then treated with ICI therapy using 15 or 20 mg alprostadil. EF was improved in 22 (68%) patients after ICI therapy. On follow up, 36% of these patients used ICI therapy only intermittently, instead of regularly, as they felt that this was adequate to generate good results (64).

Nandipati et al. evaluated early combination therapy with ICI therapy with alprostadil and oral sildenafil vs. low-dose TriMix (papaverine, phentolamine and PGE-1) vs. low-dose PGE-1 after RP in 22 patients (70). Sildenafil 50 mg/day was started at the time of hospital discharge. ICI therapy with alprostadil or low-dose TriMix was started within 3 weeks or at catheter removal. This therapy was to be attempted two to three times weekly. The patients were followed up for up to 12 months every 3 months. After a mean follow up of 6 (3–8) months, 21/22 (96%) patients were sexually active. Approximately 45% were sexually active in the injection-only group vs. 50% with combination therapy. Early ICIs following RP may facilitate early sexual intercourse, patient satisfaction and potentially earlier return of natural erections. A previous report by the same author also evaluating the role of intracavernosal alprostadil (PGE1) combined with sildenafil in stimulating early recovery of spontaneous erections following RP showed that the combination regimen assisted in early sexual activity and satisfaction (70). Furthermore, early combination therapy with sildenafil allowed a lower dose of ICIs, minimising penile discomfort (70,101).

Yessin et al. reported on combination therapy with VED and PDE5-I for early penile rehabilitation following NSRP (65). The patients were started on sildenafil, 25 mg, three times per week or tadalafil, 5 mg, twice weekly with VED being used twice daily. This combination therapy was started 11 days after RP and continued for 3 months. Overall, 56% of the patients on combination therapy obtained erections sufficient for intercourse. Patients on sildenafil reported higher success rates than those on tadalafil (78% vs. 64%) (65).

Moskovic et al. instructed their patients to take 25 mg of sildenafil nightly, as well as to use 250-µg alprostadil urethral suppositories three times per week, even beginning 1 week prior to surgery (69). Patients had to restart 25 mg of sildenafil nightly 3 days after NSRP with the addition of 250-µg alprostadil urethral suppositories three times per week once the catheter was removed. One month after RP, the patients were also instructed to use a VED at least 10 min/day, encouraged to engage in sexual activity and to use 100 mg of sildenafil on demand prior to sexual attempts. Of 29 patients originally included, 3 and 6 of the 24 patients who did not discontinue the programme (10.3% and 25%, respectively) had reported a return to natural unassisted EF sufficient for penetration at 3- and 6-month assessment, respectively. Preoperative female partner sexual function was correlated with greater patient compliance with the localised component of the EF rehabilitation programme.

A recent study, by Basal et al., demonstrated that penile rehabilitation programmes were effective for men after RP, especially ones that include PDE5-Is (66). The study demonstrated that programmes that incorporated PDE5-Is, either alone or with VEDs, were beneficial. The investigators examined the preoperative SHIM scores for 203 men, who were divided into three groups based on their degree of
Table 8 Key recommendations for ED rehabilitation programme

Key recommendations for ED rehabilitation programme

Preoperative recommendations

Preoperative discussion with the patient and their partner of the impact of surgery on sexual functioning and components of the proposed ED rehabilitation programme

The partner’s sexual function should be assessed as part of any ED management programme pre and postoperatively because partners may require medical/psychosexual therapy if they are to support rehabilitation efforts for their partners

Preoperative assessment of a couple’s readiness to engage in a ED rehabilitation programme is advisable

Preoperative assessment of comorbidities or concurrent medications, which would affect sexual function

Pre-operative assessment should include:

- Discussion of ED post surgery and its management with patient/partner
- Biomedical components, including the disease, treatment, current medications, current medical history, previous medical and surgical history and medication history
- Psychosexual therapy and counselling: to assess psychological factors (sexual self-esteem/confidence), relationship issues and any social context factors that impact on sexuality or that are affected by the sexual dysfunction
- Current sexual function (IIEF/SHIM/verbal – can the couple have penetrative intercourse?)

Postoperative recommendations

Discuss the implementation of an ED rehabilitation programme with patients and partners postoperatively

Re-assess sexual function at catheter removal or up to 10 days post surgery

Treatment algorithm

See Figure 1 for treatment algorithm recommendations for nerve-sparing prostatectomy, rectal surgery and an algorithm for non-nerve-sparing surgery

Consider first-line treatment with combination therapy

Combination therapy is usually the most cost-effective therapy (generally, PDE5-I + VED)

Consider daily PDE5-I therapy in patients with nerve-sparing surgery, especially during initial (early) management (although level 1 evidence is lacking for superiority of on-demand vs. daily treatment)

In patients with low or high risk of ED, daily therapy showed significantly higher efficacy for the EF recovery rate compared with the on-demand PDE5-I administration schedule in patients with intermediate risk of ED

Early high-dose PDE5-I may preserve the smooth muscle content within the corpora cavernosa

Add intraurethral alprostadil/ICI followed by discussion of penile implants if these initial treatment strategies fail

For non-nerve-sparing procedures, VED is generally the treatment of choice

VED is a useful adjunct to medication and facilitates early sexual activity where drugs alone are not effective

Treatment initiation

Consider initiating treatment preferably as soon as any catheter is removed and definitely within first 3 months of surgery

In some cases, PDE5-I can be initiated before surgery (if pre-existing problems are identified at presurgical assessment) or at catheter removal to improve outcomes

Psychosexual therapy and psychological counselling

Recommend psychosexual therapy or psychological counselling for patient and partner pre and postoperatively: Psychosexual therapy and counselling contribute to better biomedical treatment efficacy, patient acceptance and compliance

Encourage partner support of rehabilitation programme through ongoing psychosexual therapy and counselling for the couple and unless contraindicated, include partners in all decision-making processes

Psychosexual therapy and psychological counselling are a useful adjunct to ED rehabilitation treatments

Re-assessment

Once ED management is initiated, re-assess at regular intervals post treatment (re-assessment schedule can coincide with cancer review schedule), e.g. 8 weeks, 3 months and at 6 months

Treatment duration

Recommend to try one strategy at least on eight occasions before switching to another strategy unless the patient experiences adverse events warranting an early switch

Individualise duration of treatment for each patient as strict limits are inappropriate in clinical practice

The duration of any treatment can range from 3 months until the patient no longer needs the treatment

ED, erectile dysfunction; IIEF, International Index of Erectile Function; SHIM, Sexual Health Inventory for Men; PDE5-I, phosphodiesterase type 5 inhibitor; VED, vacuum erection device; ICI, intracorporeal injection.
ED, group 1 (SHIM = 8–16), group 2 (SHIM = 17–21) and group 3 (SHIM = 22–25). The participants then underwent four types of penile rehabilitation programmes: PDE5-Is only, VED only, combined PDE5-I and VED therapies, and no therapy. The mean EF recovery periods for groups 1, 2 and 3 were 15.44, 12.31 and 8.73 months (p < 0.05). Only PDE5-Is or the combination of PDE5-Is and VED use had a beneficial effect on EF recovery periods (p < 0.05). Using PDE5-Is and VED together provided the best result, but there was no difference between PDE5-Is and a VED when used alone (p ≥ 0.05) (66).

A study carried out in 18 patients to compare early vs. late penile rehabilitation in patients after radical cysto-prostatectomy utilised sildenafil twice weekly to be changed to ICI of PGE1 (prostaglandins) if not responding. The treatments were started at 2nd and 6th month postoperatively. Results demonstrated that early compared with delayed erectile rehabilitation brings forward the natural healing time of potency and maintains nerve-assisted erection (51).

Combination therapy can include ICI with PDE5-I, or VED and PDE5-I. Data from published studies demonstrate that a combination regimen of alprostadil and PDE5-I can assist in early sexual activity and satisfaction (70). Furthermore, early combination therapy with PDE5-I allows a lower dose of ICIs to be used, minimising penile discomfort (70,101). Data showed that early use of PDE5-Is with VED was also associated with significant benefits in sexual function (65,66,69).

Erection restoration algorithm based on clinician survey findings

The erection restoration algorithm generally used in clinical practice by survey participants for NS prostatectomy is summarised in Figure 1. In general, first-line treatment consisted of early use of PDE5-Is (daily +/- on demand) +/- VED, followed by the addition of intraurethral suppositories/ICI and implant if these strategies failed. Some participants stated that they initiate PDE5-I before surgery (if pre-existing problems identified at presurgical assessment) or at catheter removal to improve outcomes. However, for NNSRP patients, most participants agreed that PDE5-I drugs are not useful. For NNSRP, VED was generally the treatment of choice +/- ICI/intraurethral alprostadil and sexual counselling was recommended.

Although one participant recommended VED + PDE5-I for second-line use in NNSRP, most participants recommended excluding PDE5-Is for NNSRP. In general, VED is the treatment of choice +/- ICI/intraurethral alprostadil and sexual counselling was recommended for these patients.

Use of psychosexual therapy/pelvic floor exercises with the treatments described in Figure 1 depends on patient preference. Most participants agreed that the treatment schedule does not vary significantly for bladder, prostate or rectal cancer patients. However, for patients undergoing bladder surgery, presurgery ED is worse (patients are older) and recovery of EF is not optimal; therefore, a more intensive regime may be required.

Table 8 provides an Erection Restoration Algorithm from the authors for the management of erectile dysfunction after surgery.

Summary

Erectile function after RP depends on several factors that must be taken into account for adequate patient stratification and therapy. There are several options for managing ED post NS and non-NS RP. The treatment duration may range from 3 months to ≥ 6 years. Delaying the start of rehabilitation for ED is associated with poorer outcomes for EF.

Early ED rehabilitation can hopefully improve the return of spontaneous erections; facilitate early sexual intercourse, early patient/spousal sexual satisfaction, and potentially an earlier return of natural/unassisted erections sufficient for vaginal penetration.

PDE5-Is were considered first-line therapy by most clinicians. Early use of VED following RP also facilitates early sexual intercourse, early patient/spousal sexual satisfaction, and maintenance of penile length/girth and, potentially, an earlier return of natural erections. Psychological and sexual therapy and counselling emerges as an important adjunct to any rehabilitation programme and treatment of postoperative ED.

Acknowledgements

Funding for the development of this clinical guidance was provided by Prostate Cancer UK. The authors would also like to acknowledge the following organizations for supporting and endorsing this publication: the British Society for Sexual Medicine (BSSM), the British Uro-oncology Group (BUG), Macmillan and the Sexual Advice Association (SAA). The authors would also like to acknowledge Right Angle Communications for editorial assistance.

Author contributions

All authors took part in the survey for physicians, reviewed and edited the publication, which was produced by Mike Kirby and Isabel White with editorial assistance from Sabah Al-Lawati at Right Angle.
References

1 Cancer Research UK. www.cancerresearchuk.org/prod-common/docs/documents/...018070.pdf. (accessed October 2013).
2 Cancer Research UK. Bowel cancer statistics – key facts, 2010. http://www.cancerresearchuk.org/cancer-info/cancerstats/keyfacts/bowel-cancer/ (accessed October 2013).
3 Koga F, Kihara K. Selective bladder preservation with curative intent for muscle-invasive bladder cancer: a contemporary review. Int J Urol 2012; 19(5): 388–401.
4 Nandipati KC, Raina R, Agarwal A et al. Erectile dysfunction following radical retropubic prostatectomy: epidemiology, pathophysiology and pharmacological management. Drugs Aging 2006; 23: 101–17.
5 Mulhall JP, Morgentaler A. Penile rehabilitation should become the norm for radical prostatectomy patients. J Sex Med 2007; 4: 538–43.
6 Fitch MI, Miller D, Sharrt S, McAndrew A. Radical cystectomy for bladder cancer: a qualitative study of patient experiences and implications for practice. Can Oncol Nurs J 2010; 20(4): 177–87.
7 Ellis R, Smith A, Wilson S, Warming S, Ismail T. The prevalence of erectile dysfunction in post-treatment colorectal cancer patients and their interests in seeking treatment: a cross-sectional survey in the West Midlands. J Sex Med 2010; 7: 1488–96.
8 Pietrangelii A, Pugliesi P, Perrone M, Sperduti I, Cosimelli M, Jandolo B. Sexual dysfunction following surgery for rectal cancer – a clinical and neurophysiological study. J Exp Clin Cancer Res 2009; 28(12): 128.
9 Kasparek MS, Hassan J, Cima RR, Larson DR, Guillerud RE, Wolff BG. Long-term quality of life and sexual and urinary function after abdominoperineal resection for distal rectal cancer. Dis Colon Rectum 2010; 53(2): 147–54.
10 Nishizawa Y, Ito M, Saito N, Suzuki T, Sugito M, Tanaka T. Male sexual dysfunction after rectal cancer surgery. Int J Colorectal Dis 2011; 26(12): 1541–8.
11 Rogers CG, Trock BP, Walsh PC. Preservation of accessory pudendal arteries during radical retropubic prostatectomy: surgical technical and results. Urology 2004; 64: 148–51.
12 Munding M, Wessells H, Dalkin B. Pilot study of changes in stretched penile length 3 months after radical retropubic prostatectomy. Urology 2001; 58: 567–9.
13 Savoie M, Kim SS, Soloray M. A prospective study measuring penile length in men treated with radical prostatectomy for prostate cancer. J Urol 2003; 169: 1462–5.
14 Salonia A, Burnett AL, Graefen M et al. Prevention and management of postprostatectomy sexual dysfunctions. Part 1: choosing the right patient at the right time for the right surgery. Eur Urol 2012; 62: 273–86.
15 Walsh PC, Marschke P, Ricker D, Burnett AL. Patient-reported urinary continence and sexual function after anatomic radical prostatectomy. Urology 2000; 55: 58–61.
16 Rabbani F, Stapleton AM, Kattan MW et al. Factors predicting recovery of erections after radical prostatectomy. J Urol 2000; 164: 1929–34.
17 Kundu SD, Roehl KA, Egggerer SE et al. Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. J Urol 2004; 172: 2227–31.
18 Tutolo M, Briganti A, Suardi N et al. Optimizing postoperative sexual function after radical prostatectomy. Urology 2012; 6: 347–65.
19 Albaugh JA. Addressing and managing erectile dysfunction after prostatectomy for prostate cancer. Sex. Urol Oncol 2003; 16(3): 166, 167–77.
20 Forbat L, White I, Marshall-Lucette S, Kelly D. Discussing the sexual consequences of treatment in radiotherapy and urology consultations with couples affected by prostate cancer. BJU Int 2012; 109: 98–103.
21 Davison BJ, Matthew A, Elliott S, Breenon E, Griffen S. Assessing couples’ preferences for postoperative sexual rehabilitation before radical prostatectomy. BJU Int 2012; 110(10): 1529–35.
22 Chartier-Kastler E, Aman E, Chevallier D et al. Does management of erectile dysfunction after radical prostatectomy meet patients’ expectations? Results of a national survey (REPAIR) by the French Urological Association. J Sex Med 2008; 5 (3): 693–704.
23 Nehra A, Jackson G, Miner M et al. The Princeton III consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc 2012; 87(8): 766–78.
24 Smith DG, Frankel S, Yarnell J. Sexual function following radical prostatectomy: SHIM (IIEF-5) activity. J Sex Med 2005; 2: 532–54; discussion 540–542.
25 Yios R, Cinun P, de la Taille A et al. Sexual rehabilitation and penile pain associated with intracavernous alprostadil after radical prostatectomy. J Sex Med 2011; 8: 575–82.
26 Costabile RA, Spevak M, Fishman J et al. Efficacy and safety of transurethral alprostadil in patients with erectile dysfunction following radical prostatectomy. J Urol 1998; 160: 1325–8.
27 Groneo P, Fontana F, Bagnasco A et al. Is there an optimal time for intracavernous prostaglandin E1 rehabilitation following nonnerve sparing radical prostatectomy? Results from a hemodynamic prospective study. J Urol 2003; 169: 2166–9.
28 Raina R, Pahlajani G, Agarwal A, Zippr CD. The early use of transurethral alprostadil after radical prostatectomy potentially facilitates an earlier return of erectile function and successful sexual activity. BJU Int 2007; 100(6): 1317–21.
29 Raina R, Agarwal A, Zaramo CE, Ausmundson S, Mandsour D, Zippr CD. Long-term efficacy and compliance of MUSE for erectile dysfunction following radical prostatectomy: SITEM (IIIF-5) analysis. Int J Impot Res 2005; 17(1): 86–90.
30 Kölher TS, Pedro R, Hendlin K et al. A pilot study on the early use of the vacuum erection device after radical retropubic prostatectomy. BJU Int 2007; 100(4): 858–62.
31 Raina R, Agarwal A, Ausmundson S et al. Early use of vacuum constriction device following radical prostatectomy facilitates early sexual activity and potentially earlier return of erectile function. Int J Impot Res 2006; 18(1): 77–81.
32 Aydogdu O, Gokce MI, Burgu B, Baltaci S, Yaman O. Tadalafil in patients following radical prostatectomy urinary incontinence. BJU Int 2011; 108(10): 1278–83.
33 Bannowsky A, Schulze H, van der Horst C, Hautmann S, Jüenemann KP. Recovery of erectile function after nerve-sparing radical prostatectomy: improvement with nightly low-dose sildenafil. BJU Int 2008; 101(10): 1279–83.
Int J Clin Pract
ª
59 Briganti A, Gallina A, Suardi N et al. Predicting erectile function after nerve sparing radical prostatectomy and penile rehabilitation with nightly intravesical alprostadil versus sildenafil citrate. J Urol 2010; 183: 2451–6.

50 Montorsi F, Brock G, Lee J et al. Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur Urol 2008; 54(4): 924–31.

51 Mosbah A, El-Bahnasawy M, Osman Y, Hekal IA, Abou-Beih E, Shaaban A. Early versus late rehabilitation of erectile function after nerve-sparing radical cystoprostatectomy: a randomized, double-blind, placebo-controlled trial. J Urol 2004; 172(3): 1036–41.

52 Nehra A, Grantmyre J, Nadel A, Thibonnier M, Padma-Nathan H, McCullough AR, Levine LA et al. Predicting erectile function recovery after bilateral nerve-sparing radical prostatectomy: a randomized, double-blind, placebo controlled trial. J Urol 2004; 172(3): 1036–41.

53 Nehra A, Grantmyre J, Nadel A, Thibonnier M, Padma-Nathan H, McCullough AR, Levine LA et al. Predicting erectile function recovery after bilateral nerve-sparing radical prostatectomy: a randomized, double-blind, placebo controlled trial. J Urol 2004; 172(3): 1036–41.

54 Padma-Nathan H, McCullough AR, Levine LA et al.; Study Group. Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. Int J Impot Res 2008; 20(5): 479–86.

55 Lindsey I, George B, Kettlewell M, Mortensen N, Randomized, double-blind, placebo-controlled trial of sildenafil (Viagra) for erectile dysfunction after rectal excision for cancer and inflammatory bowel disease. Dis Colon Rectum 2002; 45(6): 727–32.

56 Briganti A, Di Trapani E, Abdollah F et al. Predicting erectile function recovery after bilateral nerve sparing radical prostatectomy: a proposal of a novel preoperative risk stratification. J Sex Med 2010; 7(7): 2521–31.

57 Muller A, Parker M, Waters BW, Flanigan RC, Mulhall JP. Penile rehabilitation following radical prostatectomy: predicting success. J Sex Med 2009; 6(10): 2806–12.

58 Schwartl EI, Wong P, Graydon RJ. Sildenafil preserves intracorporeal smooth muscle after radical retropubic prostatectomy. J Urol 2004; 171(2 Pt 1): 771–4.

59 Briganti A, Gallina A, Suardi N et al. Predicting erectile function recovery after bilateral nerve-sparing radical prostatectomy: a proposal of a novel preoperative risk stratification. J Sex Med 2010; 7(7): 2521–31.

60 Mulhall JP, Parker M, Waters BW, Flanigan R. The timing of penile rehabilitation after bilateral nerve-sparing radical prostatectomy affects the recovery of erectile function. BJU Int 2010; 105(1): 37–41.

61 Zippe C, Nandipati K, Agarwal A, Raina R. Sexual dysfunction following pelvic surgery. Int J Impot Res 2006; 18(1): 1–18.

62 El-Bahnasawy MS, Ismail T, Ehsoby E, Alzalouye EI, Bazeed MA. Prognostic factors predicting successful response to sildenafil after radical cystoprostatectomy. Scand J Urol Nephrol 2008; 42(2): 110–5.

63 Titta M, Tavolini IM, Moro FD, Cisternino A, Bassi P. Sexual counseling improved erectile rehabilitation after non-nerve-sparing radical retropubic prostatectomy or cystectomy – results of a randomized prospective study. J Sex Med 2006; 3: 267–73.

64 Mydlo JH, Viterbo R, Crippen P. Use of combined intracorporeal injection and a phosphodiesterase-5 inhibitor therapy for men with a suboptimal response to sildenafil and/or vardenafil monotherapy after radical retropubic prostatectomy. BJU Int 2005; 95(6): 845–6.

65 Yassin AA, Haidar A, Saad F. Favorable effects of early “penile rehabilitation” following nerve sparing radical prostatectomy. J Sex Med 2010; 8(9): 1877–83.

66 Basal S, Wambi C, Aickel C, Gupta M, Badani K. Optimal strategy for penile rehabilitation after robot-assisted radical prostatectomy based on pre-operative erectile function. BJU Int 2013; 111(4): 658–65.

67 Kimura M, Caso JR, Baize LL et al. Predicting participation in and successful outcome of a penile rehabilitation programme using a phosphodiesterase type 5 inhibitor with a vacuum erection device after radical prostatectomy. BJU Int 2012; 110(11 Pt C): E931–8.

68 Lee DJ, Cheetham P, Badani KK. Penile rehabilitation protocol after robot-assisted radical prostatectomy: assessment of compliance with phosphodiesterase type 5 inhibitor therapy and effect on early potency. BJU Int 2010; 105(3): 382–8.

69 Moskovic DJ, Mohamed O, Sathyamoorthy K et al. The female factor: predicting compliance with a post-prostatectomy erectile preservation program. J Sex Med 2010; 7(11): 3659–65.

70 Nandipati K, Raina R, Agarwal A, Zippe CD. Early combination therapy: intracavernosal injections and sildenafil following radical prostatectomy increases sexual activity and the return of natural erections. Int J Impot Res 2006; 18(5): 446–51.

71 Rubio-Aurioles E, Reyes LA, Borregales L, Caironi G, Sorsaburu S. A 6 month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Latin American men with erectile dysfunction. Curr Med Res Opin 2013; 29(6): 695–706.

72 Claes HI, Andrianne R, Opsomer R, Albert A, Bassi P. Sexual counseling improved erectile rehabilitation after robot-assisted radical prostatectomy: refusal and drop-out rates. BJU Int 2012; 110(11 Pt C): E954–7.

73 Stefaniak H, Kang J, Khursagar A et al. Tadalafil therapy beginning postoperative day one preserves erectile function after radical prostatectomy – a randomized, double-blind, placebo-controlled trial. J Urol 2012; 188(2): 410–4.

74 Schouver LR, Fouliati RT, Warneke CL et al. The use of treatments for erectile dysfunction among survivors of prostate carcinoma. Cancer 2002; 95(11): 2397–407.

75 Shindel A, Quayle S, Yan Y, Husain A, Naughton C. Sexual dysfunction in female partners of men who have undergone radical prostatectomy correlates with sexual dysfunction of the male partner. J Sex Med 2005; 2(6): 833–41.

76 Neese LE, Schover LR, Klein EA, Zippe C, Kupelian PA. Finding help for sexual problems after prostate cancer treatment: a phone survey of men’s and women’s perspectives. Psychooncology 2003; 12(5): 463–73.

77 El-Meleigy A, Rabah D, Al-Mitwalli K et al. A 6-month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Middle Eastern and North African men with erectile dysfunction. Curr Med Res Opin 2013; 29(6): 707–17.

78 Polito M, d’Anzeo G, Conti A, Muzzonigro G. Erectile rehabilitation with intracavernosal alprostadil after radical prostatectomy: refusal and drop-out rates. BJU Int 2012; 110(11 Pt C): E954–7.

79 Sato Y, Tanda H, Nakajima H et al. Dissociation between patients and their partners in expectations for sexual life after radical prostatectomy. Int J Urol 2013; 20(3): 322–8.

80 Manktelow B, Dann S. Kent Oncology Centre Survey Report. February 2009.

81 Briganti A, Capitanio U, Chun FK et al. Prediction of sexual function after radical prostatectomy. Cancer 2009; 115(13 Suppl.): 3150–9.

82 Alemezaffar M, Regan MM, Cooperberg MR et al. Prediction of erectile function following treatment for prostate cancer. JAMA 2011; 306(11): 1205–14.

83 Rosen RC, Riley A, Wagner G, Ostfeld LH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822–30.

84 Cappelleri JC, Rosen RC. The sexual health inventory for men (SHIM): a 5-year review of research and clinical experience. Int J Impot Res 2005; 17: 307–19.

85 Mulhall JP, Goldstein I, Bushmakin AG, Cappelleri JC, Hvidsten K. Validation of the erection hardness score. J Sex Med 2007; 4: 1626–34.

86 Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pena BM. Development and evaluation of an abridged, 5-item version of the international index of erectile function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999; 11: 319–26.

87 Nandipati KC, Raina R, Agarwal A, Zippe CD. Sildenafil, tadalafil, and vardenafil are equally effective treatments for erectile dysfunction after bilateral nerve sparing prostatectomy [abstract presented at the 61st Annual American Society of Reproductive Medicine meeting; October 19, 2005. Montreal, Quebec] Fertil Steril 2005; 84 (Suppl. 1): S134.

88 Stefaniak H, Kang J, Khursagar A et al. Tadalafil therapy beginning postoperative day one preserves erectile function after radical prostatectomy – preliminary results [AUA abstract]. J Am Coll Surg 2005; 201(3) (Suppl. 1): 594.

89 Hatzimouratidis K, Burnett AL, Hatzichristou D, McCullough AR, Montorsi F, Mulhall JP. Phosphodiesterase type 5 inhibitors in postprostatectomy erectile dysfunction: a critical analysis of the basic science rationale and clinical application. Eur Urol 2009; 55: 334–47.

90 Montorsi F, McCullough A. Efficacy of sildenafil citrate in men with erectile dysfunction following radical prostatectomy: a systematic review of clinical data. J Sex Med 2005; 2: 658–67.
91 Padma-Nathan H, McCullough AR, Levine LA et al.; Study Group. Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. *Int J Impot Res* 2008; 20(5): 479–86.
92 Montorsi F, Maga T, Strambi LF et al. Sildenafil taken at bedtime significantly increases nocturnal erections: results of a placebo-controlled study. *Urology* 2000; 56(6): 906–11.
93 Meuleman EI, Mulders PF. Erectile function after radical prostatectomy: a review. *Eur Urol* 2003; 43(2): 95–101.
94 Gallina A, Ferrari M, Suardi N et al. Erectile function outcome after bilateral nerve-sparing radical prostatectomy: which patients may be left untreated? *J Sex Med* 2012; 9: 903–8.
95 Kovanecz I, Rambhatla A, Ferrini M et al. Long-term continuous sildenafil treatment ameliorates corporal veno-occlusive dysfunction (CVOD) induced by cavernosal nerve resection in rats. *Int J Impot Res* 2008; 20: 202–12.
96 Lysiak JJ, Yang SK, Klausner AP et al. Tadalafil increases Akt and extracellular signal-regulated kinase 1/2 activation, and prevents apoptotic cell death in the penis following denervation. *J Urol* 2008; 179: 779e785.
97 Briganti A, Fabbrri F, Salonia A et al. Preserved postoperative penile size correlates well with maintained erectile function after bilateral nerve-sparing radical retropubic prostatectomy. *Eur Urol* 2007; 52(3): 702–7.
98 Salonia A, Gallina A, Zanni G et al. Acceptance of and discontinuation rate from erectile dysfunction oral treatment in patients following bilateral nerve-sparing radical prostatectomy. *Eur Urol* 2008; 53: 564–70.
99 Wang R. Penile rehabilitation after radical prostatectomy: where do we stand and where are we going? *J Sex Med* 2007; 4(4 Pt 2): 1085–97.
100 Sadovsky R, Basson R, Krychman M et al. Cancer and sexual problems. *J Sex Med* 2010; 7: 349–73.
101 Bronner G, Shefi S, Raviv G. Sexual dysfunction after radical prostatectomy: treatment failure or treatment delay? *J Sex Marital Ther* 2010; 36: 421–9.

*Paper received September 2013, accepted September 2013*